10 Best Penny Stocks to Buy for Long Term

7. AbCellera Biologics Inc. (NASDAQ:ABCL)

On May 12, 2026, Stifel raised the firm’s price target on AbCellera Biologics Inc. (NASDAQ:ABCL) to $8 from $7 and kept a Buy rating on the shares. The firm said preliminary safety, pharmacokinetic, and pharmacodynamic data from the single-ascending dose portion of the Phase 1 dose-escalation trial evaluating ABCL635 represent an important early step in de-risking the program longer term.

On May 11, 2026, AbCellera Biologics Inc. (NASDAQ:ABCL) reported Q1 EPS of (14c), versus the consensus estimate of (20c). Revenue totaled $8.3M, versus the consensus estimate of $5.8M. Founder and CEO Carl Hansen said interim Phase 1 data showed ABCL635 achieved strong NK3R target engagement at well-tolerated dose levels in healthy volunteers, alongside a pharmacokinetic profile that may support once-monthly dosing. Hansen added that the company expects a Phase 2 efficacy readout in Q3, which management believes could further de-risk the program.

Management also said that throughout 2026, the company plans to deliver additional clinical data readouts, advance ABCL688 and ABCL386 into IND-enabling studies, and select at least one additional development candidate. AbCellera ended the quarter with approximately $655M in available liquidity.

AbCellera Biologics Inc. (NASDAQ:ABCL) develops antibody-based medicines targeting diseases with unmet medical needs.

1281292 - 11759070 - 1